Clinical Trial Update: Study Evaluating TTI-237 in Advanced Malignant Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating TTI-237 in advanced malignant solid tumors has been terminated; Wyeth (now part of Pfizer) sponsored the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• TTI-237

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Neoplasms | Phase 1 | Status: TERMINATED